Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UK CLL Long-term Follow-up Study
2017-003593-13Phase 4Unknown
- Sponsor
- University of Leeds
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of obinutuzumab, fludarabine, cyclophosphamide, rituximab, bendamustine and 3 more in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University of Leeds. Primary endpoint: Overall survival. Status: unknown.
02
Drugs
obinutuzumabfludarabinecyclophosphamiderituximabbendamustine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2017-003593-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003593-13.